|
1) Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006; 130: 1480-91
|
|
|
|
2) Miwa H. Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria. Patient Preference and Adherence. 2008; 2: 143-7
|
|
|
|
|
|
3) Ford C, Forman D, Bailey G, et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008; 103: 1229-39
|
|
|
|
|
4) Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol. 2006; 41: 513-23
|
|
|
|
|
5) Ford AC, Marwaha A, Lim A, et al. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 2009; Available online 23 July 2009
|
|
|
|
|
|
6) Ressler J, Mayberg S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007; 10: 1116-24
|
|
|
|
|
|
7) Saito-Nakaya K, Hasegawa R, Nagura Y, et al. Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogastroenterol Motil. 2008; 20: 1147-56
|
|
|
|
|
|
8) Fukudo S, Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol. 2007; 42(suppl 17): 48-51
|
|
|
|
|
|
9) Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut. 2004; 53: 958-64
|
|
|
|
|
|
10) Ford C, Talley J, Schoenfeld S, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009; 58: 367-78
|
|
|
|
|
|
11) Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009; 136: 1979-88
|
|
|
|
|
|
12) Jung S, Kim S, Park H, et al. The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study. J Clin Gastroenterol. 2009; 43: 534-40
|
|
|
|
|
|
13) Schoepfer AM, Schafer T, Seibold-Schmid B, et al. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil. 2008; 20: 1110-8
|
|
|
|
|
|
14) Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007; 132: 26-37
|
|
|
|
|
|
15) Ohman L, Isaksson S, Lindmark C, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol. 2009; 104: 1205-12
|
|
|
|
|
|
16) Langhorst J, Junge A, Rueffer A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009; 10: 404-10
|
|
|
|
|
|
17) Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009; 30: 245-52
|
|
|
|
|
|
18) Ford C, Brandt J, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009; 104: 1831-43
|
|
|
|
|
|
19) Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008; 20: 557-65
|
|
|
|
|
|
20) Matsueda K, Harasawa S, Hongo M, et al. A randomized, double-blind, placebo-controlled crinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008; 43: 1202-11
|
|
|
|
|
|
21) Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. Available online 11 July 2009
|
|
|
|
|
|
22) Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut. 2008 Dec 17. [Epub ahead of print]
|
|
|
|
|
|
23) Brenner M, Moeller J, Chey D, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009; 104: 1033-49
|
|
|
|
|
|
24) Drossman A, Chey D, Johanson F, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009; 29: 329-41
|
|
|
|
|